Visby Medical

Visby Medical

Provides rapid PCR tests for infections

About Visby Medical

Simplify's Rating
Why Visby Medical is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Differentiation

Industries

Healthcare

Company Size

51-200

Company Stage

Grant

Total Funding

$284.5M

Headquarters

San Jose, California

Founded

2012

Overview

Visby Medical provides rapid PCR tests for detecting infectious diseases, delivering results in under 30 minutes. This is a major advancement compared to traditional PCR tests that can take days for results. Their portable testing kits are designed for use in clinical and mobile laboratory settings, making them accessible and easy to deploy. Unlike conventional PCR equipment, which is large and complex, Visby's tests are compact and instrument-free, fitting in the palm of your hand. The company primarily serves healthcare providers in the United States, focusing on improving patient care by providing quick and accurate test results. By minimizing wait times, Visby aims to reduce patient callbacks and improve follow-up care. Their goal is to enhance the efficiency of infectious disease testing, addressing the growing demand for rapid and reliable diagnostics.

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for at-home STI test boosts Visby's market position and consumer trust.
  • Recent $65M funding supports expansion and operational capabilities for new product launches.
  • CARB-X funding aids development of antibiotic resistance detection, expanding Visby's test portfolio.

What critics are saying

  • Competitors' rapid at-home test development could erode Visby's market share.
  • Regulatory challenges may delay product launches and affect market entry strategies.
  • Supply chain disruptions in semiconductor components could lead to production delays.

What makes Visby Medical unique

  • Visby Medical offers rapid PCR tests delivering results in under 30 minutes.
  • Their tests are instrument-free and compact, fitting in the palm of your hand.
  • Visby's focus on human-centric design enhances user experience and test accessibility.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$284.5M

Above

Industry Average

Funded Over

6 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Health Insurance

Health Savings Account/Flexible Spending Account

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 0%

2 year growth

↑ 1%
Cape Coral Living Magazine
Jun 17th, 2025
Visby Medical Raises $65M for At-Home STI Test

Visby Medical raised up to $65 million in a financing round led by Catalio Capital Management to accelerate the launch of its FDA-authorized at-home Women's Sexual Health Test. The funding will enhance market reach and operational capabilities. Isaac Ro from Catalio joins the board as an observer, and Chuck Alpuche joins as an independent director. The test, delivering results in 30 minutes, will be available from July 2025 through major direct-to-consumer channels.

Fierce Biotech
Mar 28th, 2025
Visby Medical nets FDA clearance for completely at-home STI test

Last month, Visby also acquired a 510(k) clearance from the FDA for its point-of-care respiratory disease test, designed to catch influenza A and B as well as the coronavirus behind COVID-19.

BioSpace
Jan 15th, 2025
Visby Medical gets $3.9M for PCR tech

Visby Medical has secured an additional $3.9 million from CARB-X to enhance its PCR-based diagnostics for antibiotic resistance, building on a previous $1.2 million grant. The funding will aid in developing tools to detect resistance mutations in infections, starting with ciprofloxacin susceptibility in Neisseria gonorrhoeae. Visby aims to integrate these capabilities into its Sexual Health Test and develop a digital app for result interpretation.

PR Newswire
Jan 15th, 2025
Visby Medical Secures Additional $3.9M from CARB-X to Fight Antibiotic Resistance with PCR-Based Mutation Detection at the POC

SAN JOSE, Calif., Jan. 15, 2025 /PRNewswire/ - Visby Medical(TM), a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to accelerate its fight against antibiotic resistance.

360Dx
Feb 9th, 2024
Visby Medical Secures $1.8M From CARB-X for Gonorrhea and Drug Resistance MDx

The portable, instrument-free PCR test will be used to detect infections resistant to the frontline antibiotic ciprofloxacin and help reduce use of ceftriaxone.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Visby Medical right now.

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →